As people age, their ability to absorb B12 from food declines due to atrophic gastritis, which reduces stomach acid production
For best results, use consistently for at least three to six months, ideally alongside attention to nutrition (particularly protein and iron levels) and any underlying causes
For individuals exploring peptide therapy options, AOD-9604s documented safety profile provides meaningful information for decision-making discussions with healthcare providers
Use Methylcobalamin 1500mcg Injection precisely as directed by your doctor
Clinical improvement often guides management more reliably than biochemical values alone

Key selective action features: No Growth Hormone Receptor Binding: Does not activate GH receptors responsible for IGF-1 stimulation and systemic growth effects Preserved Glucose Metabolism: No impact on blood sugar regulation, insulin sensitivity, or diabetic risk markers No Tissue Growth Effects: Does not promote muscle hypertrophy, organ growth, or cell proliferation pathways Adipose-Specific Targeting: Works primarily through beta-3 adrenergic receptors concentrated in fat tissue No IGF-1 Elevation: Clinical trials confirmed no changes in serum IGF-1 levels at therapeutic doses Isolated Lipolytic Action: Maintains the fat-breaking properties of growth hormone fragment 176-191 without broader effects Selective Mechanism: Structural differences from full-length GH prevent binding to receptors mediating non-fat-related effects Clinical Validation: Human studies in 900+ participants confirmed selective fat metabolism without systemic hormonal changes The following guide provides detailed analysis of AOD-9604 s selective action and why this selectivity matters for safe, targeted fat metabolism
